Tiziana Life Sciences (NASDAQ:TLSA) Announces Earnings Results

Tiziana Life Sciences (NASDAQ:TLSA) issued its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, FiscalAI reports.

Tiziana Life Sciences Price Performance

Shares of NASDAQ TLSA remained flat at $1.05 during trading on Friday. The stock had a trading volume of 553,398 shares, compared to its average volume of 388,683. Tiziana Life Sciences has a 1 year low of $0.76 and a 1 year high of $2.10. The firm has a 50-day moving average of $1.03 and a 200-day moving average of $1.16.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TLSA shares. Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. BTIG Research reaffirmed a “buy” rating on shares of Tiziana Life Sciences in a research report on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, August 26th. Finally, Wall Street Zen cut shares of Tiziana Life Sciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tiziana Life Sciences has a consensus rating of “Hold”.

Insiders Place Their Bets

In other news, CEO Ivor Elrifi acquired 237,616 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the purchase, the chief executive officer owned 4,793,684 shares of the company’s stock, valued at approximately $4,793,684. The trade was a 5.22% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders bought 988,423 shares of company stock valued at $985,909. Company insiders own 39.82% of the company’s stock.

Institutional Trading of Tiziana Life Sciences

An institutional investor recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC grew its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 12.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,900 shares of the company’s stock after acquiring an additional 12,000 shares during the period. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $131,000 at the end of the most recent reporting period.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company’s research centers on treatments designed to modulate immune responses without broadly suppressing immune function.

Tiziana’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.